Overview
Dr. Laura Rosenberger is an Associate Professor of Surgery, where she has a high-volume breast surgical oncology practice and enjoys all aspects of an academic career. She has clinical expertise and research interest in rare breast cancers, including sarcomas and a specific focus on phyllodes tumors. Dr. Rosenberger is the founding and coordinating Principal Investigator of multiple, multi-institutional studies, including a funded prospective germline testing study, and an actively accruing rare breast tumor registry with tissue biorepository. She has authored, or co-authored, over 75 peer-reviewed publications, and serves on multiple national committees including a member of the National Comprehensive Cancer Network, or NCCN, Breast Cancer Panel.
Current Appointments & Affiliations
Recent Publications
A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
Journal Article Ann Surg Oncol · August 2025 BACKGROUND: Contralateral axillary metastasis (CAM) is a rare event and is considered stage IV disease. We sought to evaluate outcomes in a CAM cohort treated with curative intent and contemporary systemic and locoregional therapy. PATIENTS AND METHODS: A ... Full text Link to item CiteAdjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes.
Journal Article Ann Surg Oncol · June 6, 2025 BACKGROUND: We examined whether adjuvant radiation therapy (RT) monotherapy offers comparable overall survival (OS) to adjuvant endocrine therapy (ET) monotherapy following lumpectomy in women aged ≥ 65 years with favorable early stage breast cancer. PATIE ... Full text Link to item CiteERBB2-Low Expression by Race and Ethnicity Among Patients With Triple-Negative Breast Cancer.
Journal Article JAMA Netw Open · June 2, 2025 IMPORTANCE: Racial and ethnic disparities in pathologic complete response (pCR) and overall survival (OS) have been reported in patients with triple-negative breast cancer (TNBC). In addition to socioeconomic factors and access to care, differences in tumo ... Full text Link to item CiteRecent Grants
Defining Actionable Opportunities in Malignant Phyllodes via Genomic Profiling
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2024 - 2027View All Grants